Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator's choice chemotherapy for advanced urothelial cancer (UC): post hoc analysis of KEYNOTE-045

J. Bellmunt; R. de Wit; D. J. Vaughn; Y. Fradet; J. L. Lee; L. Fong; N. J. Vogelzang; M. A. Climent; D. Petrylak; T. K. Choueiri; A. Necchi; W. R. Gerritsen; H. Gurney; D. I. Quinn; S. Culine; C. N. Sternberg; E. Jensen; T. Frenkl; R. F. Perini; D. Bajorin

doi:10.1093/annonc/mdy283.110

Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator's choice chemotherapy for advanced urothelial cancer (UC): post hoc analysis of KEYNOTE-045

J. Bellmunt, R. de Wit, D. J. Vaughn, Y. Fradet, J. L. Lee, L. Fong, N. J. Vogelzang, M. A. Climent, D. Petrylak, T. K. Choueiri, A. Necchi, W. R. Gerritsen, H. Gurney, D. I. Quinn, S. Culine, C. N. Sternberg, E. Jensen, T. Frenkl, R. F. Perini, D. Bajorin

Faculty of Medicine, Health and Human Sciences

Research output: Contribution to journal › Meeting abstract › peer-review

35 Downloads (Pure)

Original language	English
Pages (from-to)	viii320-viii321
Number of pages	2
Journal	Annals of Oncology
Volume	29
Issue number	Supplement 8
DOIs	https://doi.org/10.1093/annonc/mdy283.110
Publication status	Published - 1 Oct 2018
Event	43rd European Society for Medical Oncology Congress (ESMO 2018) - Munich, Germany Duration: 19 Oct 2018 → 23 Oct 2018

Bibliographical note

Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Access to Document

10.1093/annonc/mdy283.110

Publisher version (open access)Final published version, 107 KBLicence: CC BY-NC-ND

Cite this

Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J. L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D., Choueiri, T. K., Necchi, A., Gerritsen, W. R., Gurney, H., Quinn, D. I., Culine, S., Sternberg, C. N., Jensen, E., Frenkl, T., Perini, R. F., & Bajorin, D. (2018). Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator's choice chemotherapy for advanced urothelial cancer (UC): post hoc analysis of KEYNOTE-045. Annals of Oncology, 29(Supplement 8), viii320-viii321. https://doi.org/10.1093/annonc/mdy283.110

@article{b4395e68a08141e6a2d0657069b79f30,

title = "Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator's choice chemotherapy for advanced urothelial cancer (UC): post hoc analysis of KEYNOTE-045",

author = "J. Bellmunt and {de Wit}, R. and Vaughn, {D. J.} and Y. Fradet and Lee, {J. L.} and L. Fong and Vogelzang, {N. J.} and Climent, {M. A.} and D. Petrylak and Choueiri, {T. K.} and A. Necchi and Gerritsen, {W. R.} and H. Gurney and Quinn, {D. I.} and S. Culine and Sternberg, {C. N.} and E. Jensen and T. Frenkl and Perini, {R. F.} and D. Bajorin",

note = "Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.; 43rd European Society for Medical Oncology Congress (ESMO 2018) ; Conference date: 19-10-2018 Through 23-10-2018",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy283.110",

language = "English",

volume = "29",

pages = "viii320--viii321",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "OXFORD UNIV PRESS INC",

number = "Supplement 8",

}

Bellmunt, J, de Wit, R, Vaughn, DJ, Fradet, Y, Lee, JL, Fong, L, Vogelzang, NJ, Climent, MA, Petrylak, D, Choueiri, TK, Necchi, A, Gerritsen, WR, Gurney, H, Quinn, DI, Culine, S, Sternberg, CN, Jensen, E, Frenkl, T, Perini, RF & Bajorin, D 2018, 'Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator's choice chemotherapy for advanced urothelial cancer (UC): post hoc analysis of KEYNOTE-045', Annals of Oncology, vol. 29, no. Supplement 8, pp. viii320-viii321. https://doi.org/10.1093/annonc/mdy283.110

Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator's choice chemotherapy for advanced urothelial cancer (UC): post hoc analysis of KEYNOTE-045. / Bellmunt, J.; de Wit, R.; Vaughn, D. J. et al.
In: Annals of Oncology, Vol. 29, No. Supplement 8, 01.10.2018, p. viii320-viii321.

Research output: Contribution to journal › Meeting abstract › peer-review

TY - JOUR

T1 - Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator's choice chemotherapy for advanced urothelial cancer (UC)

T2 - 43rd European Society for Medical Oncology Congress (ESMO 2018)

AU - Bellmunt, J.

AU - de Wit, R.

AU - Vaughn, D. J.

AU - Fradet, Y.

AU - Lee, J. L.

AU - Fong, L.

AU - Vogelzang, N. J.

AU - Climent, M. A.

AU - Petrylak, D.

AU - Choueiri, T. K.

AU - Necchi, A.

AU - Gerritsen, W. R.

AU - Gurney, H.

AU - Quinn, D. I.

AU - Culine, S.

AU - Sternberg, C. N.

AU - Jensen, E.

AU - Frenkl, T.

AU - Perini, R. F.

AU - Bajorin, D.

N1 - Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2018/10/1

Y1 - 2018/10/1

U2 - 10.1093/annonc/mdy283.110

DO - 10.1093/annonc/mdy283.110

M3 - Meeting abstract

C2 - 32136749

SN - 0923-7534

VL - 29

SP - viii320-viii321

JO - Annals of Oncology

JF - Annals of Oncology

IS - Supplement 8

Y2 - 19 October 2018 through 23 October 2018

ER -

Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L et al. Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator's choice chemotherapy for advanced urothelial cancer (UC): post hoc analysis of KEYNOTE-045. Annals of Oncology. 2018 Oct 1;29(Supplement 8):viii320-viii321. doi: 10.1093/annonc/mdy283.110